股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 第 1 頁 共 10 頁 v 1.1.0 FF301 呈交日期: 2024年10月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | ...

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2024-05 | --- | --- | --- | |-------------------------|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 √ 现场参观 □ 其他 | □ 分析师会议 \n □ 业绩说明会 \n □ 路演活动 | | 参与单位名称及 人员姓名 | 等 10 余家机构 | 中金公司、招商证券、高毅资产、国泰基金 ...

Financial Performance - For the six months ended June 30, 2024, the company reported total revenue of RMB 5,604.5 million, a decrease of approximately RMB 35.7 million or 0.6% compared to the same period in 2023[8]. - The gross profit for the same period was RMB 1,848.1 million, reflecting a decline of 9.3% from RMB 2,037.4 million in the previous year[8]. - Profit attributable to equity holders of the parent increased by approximately 41.6% to RMB 1,113.4 million, compared to RMB 786.1 million for the six months ended June 30, 2023[9]. - The net cash flow from operating activities was approximately RMB 1,099.7 million, down 14.1% from RMB 1,280.2 million in the same period last year[9]. - The company achieved a net profit attributable to shareholders of RMB 1,113.4 million, an increase of 41.6% year-on-year[12]. - The company’s adjusted net profit under IFRS was RMB 690.3 million, a decrease of 25.9% year-on-year[12]. - The company reported a total of RMB 50,026,000 in current liabilities related to derivative financial instruments as of June 30, 2024, compared to RMB 26,931,000 as of December 31, 2023, showing an increase of approximately 85.5%[164]. - The total comprehensive income for the period was RMB 1,050,416 thousand, compared to RMB 821,211 thousand in the previous year, indicating a growth of 28%[124]. Revenue Breakdown - In Q2 2024, the company achieved revenue of RMB 2,933.7 million, representing a 9.9% increase compared to Q1 2024, indicating a recovery in the global biopharmaceutical investment and financing environment[11]. - Revenue from European customers (including the UK) was RMB 945.6 million, a year-on-year increase of 10.0%, accounting for 16.9% of total revenue[12]. - Revenue from North American customers was RMB 3,668.2 million, accounting for 14.1% of total revenue[12]. - The laboratory services segment generated revenue of RMB 3,371.2 million, a slight decrease of 0.3% year-on-year, with a gross margin of 44.0%[13]. - CMC (small molecule CDMO) services generated revenue of RMB 1,175.7 million, a decrease of 6.0% year-over-year; Q2 2024 revenue was RMB 593.6 million, reflecting a 2.0% increase from Q1 2024[14]. - Clinical research services achieved revenue of RMB 843.3 million, a 4.7% increase year-over-year; Q2 2024 revenue was RMB 451.7 million, up 15.4% from Q1 2024[15]. - The company's revenue from macromolecule and cell gene therapy services reached RMB 211.2 million, representing a 5.5% increase compared to the same period last year[16]. Customer Base and Market Position - The company served over 2,200 global customers in the first half of 2024, with multi-segment customers contributing RMB 3,987.9 million, representing 71.2% of total revenue[12]. - The company added over 360 new customers, contributing RMB 161.2 million to total revenue[12]. - 97% of the company's revenue comes from a large, diverse, and loyal repeat customer base, enhancing sustainable growth[31]. - The global biopharmaceutical industry is showing signs of recovery, with financing amounts for biotech companies returning to growth, indicating a preliminary revival in customer demand[32]. Operational Efficiency and Strategy - The company is focused on building a multi-therapy, full-process integrated service platform, aiming to become a global leader in drug development services[10]. - The company continues to strengthen its international capabilities to provide cross-disciplinary, cross-regional, and cross-border collaborative service solutions[10]. - The company is committed to improving management efficiency and service capabilities to meet market and customer demands[10]. - The company emphasizes continuous investment in technology and innovation, particularly in AI, to support its research and development capabilities[22]. - The company has established a comprehensive drug research and development service platform, enhancing its competitive advantage in the pharmaceutical industry[26]. Sustainability and Corporate Governance - The company’s scientific carbon targets were officially verified by SBTi, indicating a commitment to sustainability and carbon reduction initiatives[12]. - The company is committed to environmental protection, health, safety, and intellectual property rights, ensuring client trust and recognition[31]. - The company has established a DEI (Diversity, Equity, and Inclusion) management structure to ensure effective implementation of DEI policies across governance and operational levels[50]. - The company has actively responded to national initiatives for renewable energy use, with domestic parks already implementing green electricity applications and overseas parks utilizing biomass energy and photovoltaic power generation[63]. Human Resources and Employee Engagement - The company has established a comprehensive training system, including the Kanglong Academy, to enhance employee skills and research capabilities[31]. - The company emphasizes talent acquisition and retention, aiming to attract top drug development talent and enhance its internal training platform[38]. - The company has implemented a systematic training program for all employees and contractors to ensure understanding of company policies and job responsibilities[51]. - The company provides 10 days of paid parental leave and flexible part-time work arrangements in the UK and US locations[54]. Financial Position and Investments - As of June 30, 2024, the total current assets amounted to approximately RMB 7,071.2 million, compared to RMB 10,874.4 million as of December 31, 2023[20]. - The total liabilities to total assets ratio (leverage ratio) improved to 40.5% as of June 30, 2024, down from 50.0% as of December 31, 2023[20]. - The company completed the sale of its stake in Proteologix, Inc. to Johnson & Johnson for approximately USD 102 million, receiving a net payment of USD 86.195 million after transaction costs[22]. - The company has outstanding bank loans totaling RMB 5,179,140,000, with RMB 852,040,000 due within one year, compared to RMB 727,412,000 in the previous year, indicating a year-over-year increase of 17.1%[171]. Risks and Challenges - The company faces regulatory risks related to drug development and production, which could impact its operations if it fails to meet compliance requirements[44]. - The company is exposed to foreign exchange risks primarily related to USD, GBP, and EUR, with a significant portion of its revenue coming from USD-denominated sales[45]. - The competitive landscape is expected to intensify as more competitors enter the market, impacting various factors such as service quality and pricing[47].

2023 年 10 月 18 日，康龙化成（北京）新药技术股份有限公司（以下简称 "公司"）召开了第三届董事会第三次会议和第三届监事会第三次会议，分别审 议通过了《关于投资参股境外公司暨关联交易的议案》，同意公司以自有资金 1,050 万美元通过全资子公司 Pharmaron (Hong Kong) International Limited（以下 简称"康龙香港国际"）与合作方 CMS MEDICAL VENTURE PTE. LTD.、Rxilient Health Pte. Ltd.、HEALTHY GOAL LIMITED 共同投资位于新加坡的 Rxilient Biohub Pte. Ltd.（现更名为 PharmaGend Global Medical Services Pte. Ltd.，以下简 称"合资公司"）。关联董事李家庆先生已在董事会上对该议案回避表决，独立董 事对此发表了事前认可意见和同意的独立意见。具体内容详见公司于 2023 年 10 月 19 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于投资参股境外公司暨 关联交易的公告》（公告编号：2023-093）。 20 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-063 康龙化成（北京）新药技术股份有限公司 2024年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会是否出现否决提案的情形：否。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1．康龙化成（北京）新药技术股份有限公司（以下简称"公司"）2024 年第 一次临时股东大会（以下简称"本次股东大会"）通知公告已于 2024 年 8 月 28 日以公告形式发出。 2．会议召开的时间： （1）现场会议召开时间：2024 年 9 月 13 日（星期五）14:30； （1）2024 年第一次临时股东大会出席情况 | 2024 年第一次临时股东大会： | | | | --- | --- | --- | | 1、出席会议的股东和代理人数 | | 531 | | 其中：A | 股股东人数 | 530 | | 境外上市外资股股东人数（H | 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | | 710,1 ...

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 2024 年第一次临时股东大会的 法律意见书 致：康龙化成（北京）新药技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等 规定，北京市中伦律师事务所（以下简称"本所"）接受康龙化成（北京）新药 技术股份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2024 年 第一次临时股东大会（以下简称"本次股东大会"）进行见证并就相关事项出具 本法律意见书。 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 2. 提供给本所的文件中所述的全部事实都是真实、准确、完整的； 3. 提供给本所的文件的签署人均具有完全民事行为能力，并且其签署行为 已获得恰当、有效的授权； 4. 所有提供给本所的复印件与原件一致， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2024年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | | 1 RMB | ...

公 司 研 究 医 药 生 物 康龙化成 沪深300 2024年09月03日 买入（维持） 报告原因：业绩点评 证券分析师 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn | --- | --- | |--------------------------|------------------| | | | | 数据日期 收盘价 | 2024/09/02 19.50 | | 总股本 ( 万股 ) | 178,673 | | 流通 A 股 /B 股 ( 万股 ) | 142,094/0 | | 资产负债率 (%) | 40.55% | | 市净率 ( 倍 ) | 2.55 | | 净资产收益率 ( 加权 ) | 8.54 | | 12 个月内最高 / 最低价 | 37.00/17.70 | -50% -38% -26% -14% -2% 10% 22% 35% 23-09 23-12 24-03 24-06 相关研究 《康龙化成（300759）：一体化龙头 彰显韧性，业务间导流贡献增长动力 —公司简 ...

隐证券 医药生物/医疗服务 公 司 研 究 康龙化成（300759.SZ） 2024 年 08 月 30 日 收入端环比改善，新签订单持续稳健增长 ——公司信息更新报告 0.6%；实现归母净利润 11.1 亿 归母净利润 6.9亿元，同比下滑 25.9%。 0.6%，环比增长 9.9%；实现归母 282.9%；实现经调整 Non-IFRS ，环比增长 3.6%。公司收入端环比稳健 被合并收购，归母净利润实现强劲增长。 2024H1 公司新签订单同比增长超 15%，连续两个季度实现温和复苏。我们看好 公司长期发展，维持原盈利预测，预计 2024-2026 年公司归母净利润为 17.84/20.03/23.98 亿元，EPS 为 1.00/1.12/1.34 元，当前股价对应 PE 为 19.9/17.7/14.8 倍，鉴于公司新签订单增速稳健，维持"买入"评级。 | --- | --- | --- | --- | |-------------------------------|-------------|----------------------------------------------------- ...

股票代码：300759.SZ 股票代码：3759.HK 2024 中期报告说明会 前瞻性陈述 本演示文稿呈现的文件、观点和材料（以下简称"文件"）由康龙化成(北京)新药技术股份有限公司(以下简称"公司")编制，供本公司在演示文稿中用于报告使用，不构成对本公司有关证券的推荐。您完 全理解该文件是在保密的基础上提供的，并遵守以下规定。本文件内容未经任何司法管辖区的任何监管机构审核。在某些司法管辖区，本文件的分发可能受到法律的限制，持有本文件的收件人应告 知自己并遵守这些限制。通过访问本文件，即表示您同意(i)您已阅读并同意遵守本文件通知和免责声明的内容，以及(ii)对在本文件中披露的信息绝对保密。 本文件未经独立核实，不构成任何投资决策的依据。不构成要约或邀请,也不构成在任何司法管辖区域内要求认购或购买任何证券的要约邀请（报价）,在根据该司法管辖区的证券法进行注册或取得资 格之前，征集或出售都将是非法的，或者不符合该司法管辖区的法律法规，并且文件中的任何内容均不构成任何投资决策、合同或承诺的基础。本文件不包含任何可能导致被视为(1)广告的信息或材 料，包含在《证券及期货条例》(香港法律第571章)("证券及期货条 ...